GLP-1 Weight Loss Plotter
Interactive projection tool based on STEP, SURMOUNT, and TRIUMPH trial data. Enter your starting weight and protocol; see your realistic trajectory with confidence bands reflecting the actual variance observed in human trials.
Plot Your Projected Trajectory
Enter your starting weight and pick a GLP-1. The chart models the published trial average with a realistic plateau and a ±10% individual-variance band. This is a projection from clinical-trial averages, not a personalized prediction.
Curves model the trial-average total loss approaching a plateau (exponential fit to the published endpoint). Your actual result depends on dose adherence, titration, diet, and individual response. Educational purposes only — not medical advice.
How It Works
Wegovy / Ozempic data. Average 15% body weight loss at 68 weeks; wide variance. Titration over 16 weeks to 2.4mg weekly. The established curve.
Mounjaro / Zepbound data. Average 22.5% at 72 weeks on top dose. Titration over 20 weeks to 15mg weekly. Steeper initial slope, delayed plateau.
Triple agonist, not yet approved. Phase 2 data shows ~24% at 48 weeks. Phase 3 ongoing; projection bands reflect the tighter sample size.
Most GLP-1 users hit a plateau around weeks 20-40. The plotter models this non-linearity rather than assuming constant weekly loss, which overestimates late results.
What the Data Shows
Key Takeaways
- Published STEP, SURMOUNT, and TRIUMPH data give clear average trajectories
- Most individuals land within ±10% of the trial mean
- Plateau inflection is real and happens around weeks 20-40 on most protocols
- Titration schedule significantly affects tolerance and side effects
- Food quality and protein intake matter independently of the peptide
- Projections are averages; your individual response depends on genetics, diet, and adherence
- Trial populations were mostly BMI 30+ — results may differ at lower BMI
- Stopping the drug typically leads to weight regain (~2/3 within a year)
- Tool does not account for muscle loss risk (see glp1-muscle-loss page)
- Does not replace medical supervision — this is projection, not prescription
Frequently Asked Questions
How accurate is the projection?
The plotter anchors each curve to the published trial-average total loss (STEP, SURMOUNT, TRIUMPH) and models the approach-to-plateau between your start weight and that endpoint. It is a population-average projection, not a personalized prediction; individual results commonly vary by about ±10%.
Can I plot cycling protocols?
Not yet — current plotter assumes continuous dosing as studied. Cycling protocols don't have published trial data and projections would be guesswork.
Why does my trajectory flatten?
The GLP-1 plateau is real and biological. Receptor downregulation, adaptive metabolism, and behavioral compensation all contribute. Most people lose most of their total weight in the first 6 months.
What about compounded semaglutide?
Dose-equivalent compounded semaglutide should produce similar trajectories if the product is pure. Quality varies; check your compounding pharmacy credentials.
Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links support HighPeptides at no extra cost.
Projections are based on published clinical trial data. Individual results vary. The plotter is a planning tool, not medical advice.
Always work with a qualified healthcare provider for weight-loss therapy. GLP-1 drugs are prescription medications with real side-effect profiles.
Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.